Toward a biology of autism: Possible role of certain neuropeptides and neurotrophins

Clinical Neuroscience Research

Volumn 1, Issue 4, 2001, Pages 300-306

  Nelson, Karin B ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Autism; Neuropeptides; Neurotrophins

Indexed keywords

EID: 0347117528     PISSN: 15662772     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1566-2772(01)00016-0     Document Type: Article

References (55)

1. Kanner L. Autistic disturbances of affective contact. Nervous Child 1943;2:217-250.
2. Folstein S, Rutter M. Infantile autism: a genetic study of 21 twin pairs. J Child Psychol Psychiatry 1977;18:297-321.
3. Bailey A, Le Couteur A, Gottesman I, Bolton P, Simonoff E, Yuzda E, Rutter M. Autism as a strongly genetic disorder: evidence from a British twin study. Psychol Med 1995;25:63-77.
4. Mahoney WJ, Szatmari P, MacLean JE, Bryson SE, Bartolucci G, Walter SD, et al. Reliability and accuracy of differentiating pervasive developmental disorder subtypes. J Am Acad Child Adolesc Psychiatry 1998;37:278-285.
5. Gillberg C, Wing L. Autism: not an extremely rare disorder. Acta Psychiatr Scand 1999;99:399-406.
6. Fombonne E. Epidemiological surveys of autism. In: Volkmar F, editor. Autism and pervasive developmental disorders, Cambridge, UK: Cambridge University Press, 1998. pp. 33-63.
7. Filipek PA, Accardo PJ, Ashwal S, Baranek GT, Cook Jr EH, Dawson G, et al. Practice parameter: screening and diagnosis of autism. Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Child Neurology Society. Neurology 2000;55:468-479.
8. Nelson KB, Grether JK, Croen LA, Dambrosia JM, Dickens BF, Jelliffe LL, Hansen RL, Phillips TM. Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation. Ann Neurol 2001;49.
9. Kemper TL, Bauman M. Neuropathology of infantile autism. J Neuropathol Exp Neurol 1998;57:645-652.
10. Bailey A, Luthert P, Dean A, Harding B, Janota I, Montgomery M, Rutter M, Lantos P. A clinicopathological study of autism. Brain 1998;121:889-905.
11. Stromland K, Nordin V, Miller M, Akerstrom B, Gillberg C. Autism in thalidomide embryopathy: a population study. Dev Med Child Neurol 1994;36:351-356.
12. Rodier PM, Ingram JL, Tisdale B, Nelson S, Romano J. Embryological origin for autism: developmental anomalies of the cranial nerve motor nuclei. J Com Neurol 1996;370:247-261.
13. Ingram JL, Stodgell CJ, Hyman SL, Figlewicz DA, Weitkamp LR, Rodier PM. Discovery of allelic variants of HOXA1 and HOXB1: genetic susceptibility to autism spectrum disorders. Teratology 2000;62:393-405.
14. Grether JK, Cummins SK, Nelson KB. The California Cerebral Palsy Project. Paediatr Perinat Epidemiol 1992;6:339-351.
15. Nelson KB, Dambrosia JM, Grether JK, Phillips TM. Neonatal cytokines and coagulation factors in children with cerebral palsy. Ann Neurol 1998;44:665-675.
16. Phillips TM, Krum JM. Recycling immunoaffinity chromatography for multiple analyte analysis in biological samples. J Chromatogr B Biomed Sci Appl 1998;715:55-63.
17. Phillips TM, Dickens BF. Affinity and Immunoaffinity Purification Techniques, BioTechnique Books. Natiack, MA: Eaton Press, 2000.
18. Pellegri G, Magistretti PJ, Martin J-L. VIP and PACAP potentiate the action of glutamate on BDNF expression in mouse cortical neurons. Eur J Neurosci 1998;10:272-280.
19. Gressens P, Paindaveine B, Hill JM, Evrard P, Brenneman DE. Vasoactive intestinal peptide shortens both G1 and S phases of neural cell cycle in whole postimplantation cultured mouse embryos. Eur J Neurosci 1998;10:1734-1742.
20. Brenneman DE, Hauser J, Phillips TM, Davidson A, Bassan M, Gozes I. Vasoactive intestinal peptide: link between electrical activity and glia-mediated neurotrophism. Ann NY Acad Sci 1999;897:17-26.
21. Bellinger DL, Lorton D, Brouxhon S, Felten S, Felten DL. The significance of vasoactive intestinal polypeptide (VIP) in immunomodulation. Adv Neuroimmunol 1996;6:5-27.
22. Pozo D, Delgado M, Martinez C, Guerrero JM, Leceta J, Gomariz RP, Calvo JR. Immunobiology of vasoactive intestinal peptide (VIP). Immunol Today 2000;21:7-10.
23. Magistretti P. VIP neurons in the cerebral cortex. Trends in Pharmacol Sci 1990;11:250-254.
24. Bajo AM, Juarranz MG, Valenzuela P, Martinez P, Prieto C, Guijarro LG. Expression of vasoactive intestinal peptide (VIP) receptors in human uterus. Peptides 2000;21:1383-1388.
25. Martinez C, Delgado M, Abad C, Gomariz RP, Ganea D, Leceta J. Regulation of VIP production and secretion by murine lymphocyts. J Neuroimmunol 1999;93:126-138.
26. Ward NL, Hagg T. BDNF is needed for postnatal maturation of basal forebrain and neostriatum cholinergic neurons in vivo. Exp Neurol 2000;162:297-310.
27. Hohmann CF, Berger-Sweeney J. Cholinergic regulation of cortical development and plasticity. Perspect Devel Neurobiol 1998;5:401-425.
28. Sklair-Tavron L, Nestler EJ. Opposing effects of morphine and the neurotrophins NT-3, NT-4, and BDNF, on locus coeruleus neurons in vitro. Brain Res 1995;702:117-125.
29. Marty S, Berninger B, Carroll P, Thoenen H. GABAergic stimulation regulates the phenotype of hippocampal interneurons through the regulation of brain-derived neurotrophic factor. Neuron 1996;16:565-570.
30. Zhou J, Iacovitti L. Mechanisms governing the differentiation of a serotonergic phenotype in culture. Brain Res 2000;877:37-46.
31. Mossner R, Daniel S, Albert D, Heils A, Okladnova O, Schmitt A, Lesch KP. Serotonin transporter function is modulated by brain-derived neurotrophic factor (BDNF) but not nerve growth factor (NGF). Neurochem Int 2000;36:197-202.
32. Jankowsky JL, Patterson PH. Cytokine and growth factor involvement in long term potentiation. Mol Cell Neurosci 1999;14:273-286.
33. Ickes BR, Pham TM, Sanders LA, Aalbeack DS, Mohammed AH, Granholm A-C. Long-term environmental enrichment leads to regional increases in rat brain. Exp Neurol 2000;164:45-52.
34. Spong CY, Lee SJ, McCune SK, Gibney G, Abebe DT, Alvero R, et al. Maternal regulation of embryonic growth: the role of vasoactive intestinal peptide. Endocrinol 1999;140:917-924.
35. Nakahashi T, Fujimura H, Altar CA, Li J, Kambayashi J, Tandon NN, Sun B. Vascular endothelial cells synthesize and secrete brain-derived neurotrophic factor. FEBS Lett 2000;470:113-117.
36. Barouch R, Appel E, Kazimirsky G, Braun A, Renz H, Brodie C. Differential regulation of neurotrophin expression by mitogens and neurotransmitters in mouse lymphocytes. J Neuroimmunol 2000;103:112-121.
37. Charman T. Autism and pervasive developmental disorders. Curr Opin Neurol 1999;12:155-159.
38. Miles JH, Hadden LL, Takahashi TN, Hillman RE. Head circumference is an independent clinical finding associated with autism. Am J Med Genet 2000;95:339-3350.
39. Lainhart JE, Piven J, Wzorek M, Landa R, Santangelo SL, Coon H, Folstein SE. Macrocephaly in children and adults with autism. J Am Acad Child Adolesc Psychiatr 1997;36:282-290.
40. White DM, Walker S, Brenneman DE, Gozes I. CREB contributes to the increased neurite outgrowth of sensory neurons induced by vasoactgive intestinal peptide and activity-dependent neurotrophic factor. Brain Res 2000;868:31-38.
41. Feng L, Wang CY, Jiang H, Oho C, Dugich-Djordjevic M, Mei L, Lu B. Differential signaling of glial cell line-derived neurotrophic factor and brain- derived neurotrophic factor in cultured ventral mesencephalic neurons. Neurosci 1999;93:265-273.
42. Pizzorusso T, Ratto GM, Putignano E, Maffei L. Brain-derived neurotrophic factor causes cAMP response element-binding protein phosphorylation in absence of calcium increases in slices and cultured neurons from rat visual cortex. J Neurosci 2000;20:2809-2816.
43. Horvath K, Papadimitrious JC, Rabsztyn A, Drachenberg C, Tildon JT. Gastrointestinal abnormalities in children with autistic disorder. J Pediatr 1999;135:559-563.
44. Chez MG, Nowinski CV, Buchanan CP. Presence of gastrointestinal symptoms in children with primary diagnoses of autistic disorder [abstract]. Ann Neurol 2000;48:542.
45. Wakefield AJ, Anthony A, Murch SH, Thomson M, Montgomery SM, Davies S, et al. Enterocolitis in children with developmental disorders. Am J Gastroenterol 2000;95:2285-2295.
46. Di Sebastiano P, Fink T, di Mola FF, Weihe E, Innocenti P, Friess H, Buchler MW. Neuroimmune appendicitis. Lancet 1999;34:461-466.
47. Asano E, Kuivaniemi H, Huq M, Tromp G, Behen M, Rothermel R, Herron J, Chugani DC. Novel polymorphisms in the upstream region of VIPR2 gene suggest a possible role in gastrointestinal problems and stereotypical behaviors in autism [abstract]. Am J Hum Genet 2000;67:889.
48. Schreck KA, Mulick JA. Parental report of sleep problems in children with autism. J Aut Dev Disord 2000;30:127-135.
49. Elia M, Ferri R, Musumeci SA, Del Gracco S, Bottitta M, Scuderi C, et al. Sleep in subjects with autistic disorder: a neurophpysiological and psychological study. Brain Dev 2000:88-92.
50. Lord C, Leventhal BL, Amaral DG. Autism spectrum disorders. Neuron 2000;28:355-363.
51. Young LJ, Nilsen R, Waymire KGG, MacGregor GR, Insel TR. Increased affiliative response to vasopressin in mice expressing the Via receptor from a monogamous vole. Nature 1999;400:766-768.
52. Ferguson JN, Young LJ, Hearn EF, Matzuk MM, Insel TR, Winslow JT. Social amnesia in mice lacking the oxytocin gene. Nat Genet 2000;25:284-288.
53. Wu JY, Henins KA, Gressens P, Gozes I, Fridkin M, Brenneman DE, Hill JM. Neurobehavioral development of neonatal mice following blockade of VIP during the early embryonic period. Peptides 1997;18:1131-1137.
54. Gozes I, Bachar M, Bardea A, Davidson A, Rubinraut S, Fridkin M. Protection against developmental deficiencies by a lipophilic VIP analogue. Neurochem Res 1998;23:689-693.
55. Chao MV. Trophic factors: an evolutionary cul-de-sac or door into higher neuronal function? J Neurosci Res 2000;59:353-355.